Our in vivo experiments revealed that tumors derived from SORT1-silenced HCC cells exhibited reduced staining of angiogenesis markers, including CD31 and VEGF, as well as and the EMT marker Vimentin, in both subcutaneous and orthotopic xenograft models. This evidence concerns the gene SORT1 and hepatocellular carcinoma.